AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46 th Annual Global Healthcare Conference at 9:20 a.m. PT on Tuesday, June 10, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , YouTube and Threads .

CONTACT: Amgen, Thousand Oaks
Elissa Snook , 609-251-1407 (media)
Justin Claeys , 805-313-9775 (investors)

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-goldman-sachs-46th-annual-global-healthcare-conference-302473438.html

SOURCE Amgen

News Provided by PR Newswire via QuoteMedia

AMGN:US
The Conversation (0)
Amgen Inc.

Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Doctor using a tablet with floating medical icons and holographic brain.

How AI is Poised to Rewire the Foundations of Medicine

At Web Summit Vancouver, experts speaking on the panel "A History of the Future of Healthcare" delivered a striking message: medicine is moving faster than ever, but it's not fast enough.

This paradox set the stage for a discussion about the transformation of healthcare via artificial intelligence (AI).

While many industries have been completely revolutionized by technology, the healthcare sector has often lagged, clinging to outdated practices. However, the participants agreed that AI is beginning to change that narrative, offering promising solutions and a glimpse into a future of personalized, efficient and proactive care.

Keep reading...Show less
BetterInvesting Magazine Update on The Walt Disney Co.

BetterInvesting Magazine Update on The Walt Disney Co.

Based on recent updated information, the Securities Review Committee of BetterInvesting Magazine has revised its previous decision pertaining to Stride Inc.'s announced selection as the "Stock to Study" for the August 2025 issue. The Walt Disney has been chosen instead as the "Stock to Study" for August.

The Walt Disney Co.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine consider Disney (NYSE:DIS) as worthy of further study and has named the company its "Stock to Study" for the August 2025 issue for investors' informational and educational use.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

Phase 1 1 First-In-Human study designed to assess safety   ,   tolerability   , right dose for Phase 2 and early signs of efficacy   of 177Lu-RAD20   2   in individuals with   advanced HER2-positive solid   tumors

Previous clinical proof-of concept data 2 for targeting HER-2 demonstrated the safety and biodistribution of 99mTc-RAD202 in humans

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Two vials labelled "H5N1 Vaccine." One stands and one lays on its side behind the first.

Bird Flu Vaccine Stocks: 8 Companies Developing H5N1 Vaccines

Life science companies developing bird flu vaccines and antivirals are gaining attention as the avian influenza subtype H5N1 becomes an increasing concern.

The United States is in the midst of an H5N1 bird flu outbreak that began in February 2024 and is now threatening the nation’s poultry and cattle industries. With poultry farmers across the US needing to cull their flocks if the virus is detected to prevent it spread, egg prices are shocking shoppers at the country’s grocery stores. Highly pathogenic avian influenza (HPAI) has also spread to cattle and other mammals, including cats.

Human avian influenza cases have so far been rare during this outbreak in the US, as currently the virus is only spread to humans through exposure to infected animals. As of May 30, 2025, 70 human cases have been detected in the country, and one death has been reported. However, concerns such as the possibility of mutations that could increase the chance of human-to-human transmission are stoking calls for better preparedness and access to bird flu vaccines.

Keep reading...Show less

Latest Press Releases

Related News

×